- Research article
- Open Access
Is there a place for Tooth Mousse® in the prevention and treatment of early dental caries? A systematic review
BMC Oral Health volume 15, Article number: 113 (2015)
It is important for Dental Professionals to consider the evidence for the effectiveness of the preventive strategies used to maintain good oral health and reduce the risk of caries in their patients. Whilst many of the traditional preventive activities, including the recommendation and use of fluoride products and the placement of fissure sealants have a wealth of clinical evidence to support their use, some of the newer preventive agents have a more limited evidence base. In order to investigate the level of scientific support behind one such technology, a systematic literature review was carried out to assess the effectiveness of Tooth Mousse® (MI Paste®) and Tooth Mousse Plus® (MI Paste Plus®) in the prevention and treatment of early dental caries.
A broad search strategy using Medline via OvidSP and EMBASE was performed in order to capture all published studies to related Casein Phosphopeptide-Amorphous Calcium Phosphate. In addition to the above searches the terms “CPP ACP” and “casein phosphopeptide amorphous calcium phosphate” were searched using PREMEDLINE and the Cochrane Central Register of Controlled Trials. Inclusion criteria were clinical trials of participants of any age, comparing the use of Tooth Mousse® (MI Paste®) or Tooth Mousse Plus® (MI Paste Plus®) to a routine oral care regimen and reporting recognised clinical outcome measures for early caries lesions. Only research studies in English were selected.
7576 articles were identified, but the majority were duplicates. Once these were removed 172 articles were inspected and the focus on ‘CPP-ACP formulations of Tooth Mousse® (MI Paste®) and Tooth Mousse Plus® (MI Paste Plus®) resulted in 29 articles being selected, and of these 12 studies met the inclusion criteria and were considered acceptable for the systematic review.
The overall findings of this review did not show any significant benefits of using Tooth Mousse® (MI Paste®) products over brushing with a fluoride toothpaste for the prevention of early dental caries. With regard to the regression of white spot lesions in orthodontic patients there is a tendency towards a benefit for the use of Tooth Mousse® (MI Paste®) but the quality of evidence is limited. There is a lack of evidence to support the use of Tooth Mousse Plus® (MI Paste Plus®) over Tooth Mousse® (MI Paste®) at this time.
This review suggests that further well-designed randomized controlled trials are required prior to the widespread recommendation of Tooth Mousse® products for the prevention and treatment of early dental caries in the general population.
Forty years ago dental caries was a major health problem for most children and adults living in developed countries and the dental profession was unable to cope with the demand for clinical care . Since then the prevalence and severity of dental caries has declined. For example the mean DMFT for 12 year olds in Australia dropped from 4.8 in 1977 to 1.1 in 1993  and in the United Kingdom from 3.1 in 1973 to 0.8 in 2003 . The change in caries prevalence has been accompanied by an alteration in the distribution of lesions, with pit and fissure caries levels increasing . Despite the general improvements in oral health, caries continues to be a challenge for the dental team, particularly for those clinicians working in low income and socially disadvantaged areas where the prevalence of caries is still a public health issue. Another change that has had an impact on clinical practice is the increased prevalence of new carious lesions in adults, reaching a level as high as that seen in children . Therefore, the profession has to plan treatment and preventive care pathways based on the understanding that dental caries is no longer a rapidly developing problem in childhood, but a slowly progressing disease of adulthood.
The general decline in dental caries that has occurred may have led to some complacency amongst the dental team when considering the impact preventive care can have on patients. This conundrum is demonstrated in a study which found that 25 % of children initially caries free developed caries over the following three years and those with one carious lesion were five times more likely to develop more lesions when compared with those free of the disease . Therefore professionals who only provide preventive advice to those with dental caries will be doing a disservice to many patients.
Given that oral health care advice is a key part of the dental service for patients it is important to consider the evidence for the effectiveness of our preventive activities. We want to be confident we can maintain good oral health and reduce the risk of caries.
There are four potential preventive strategies which can be used by the dental team, namely
Regular disturbance of the plaque biofilm by brushing twice a day with a fluoride toothpaste . Other fluoride agents may also be added if the caries risk warrants their use [8–11].
Reduction in the frequency of consumption of refined carbohydrate .
Placement of pit and fissure sealants, to address the increase in occlusal caries .
Regular monitoring of early carious lesions to check for progression and determine if fluoride products are being used appropriately. Reinforcement of lifestyle changes such as controlling the frequency of sugar consumption and brushing with a fluoride toothpaste twice a day .
It is clear that there is a wealth of scientific evidence supporting these preventive strategies, especially the use of fluorides. However research scientists have also investigated other agents which could be of value in helping the dental team and their patients to control dental caries. Ones which have achieved great popularity are Tooth Mousse® (MI Paste®) and Tooth Mousse Plus® (MI Paste Plus®) containing the active ingredient casein phosphopeptide – amorphous calcium phosphate (CPP-ACP) and are marketed by the GC Corporation.
These products are based on the pioneering work of Professor Eric Reynolds and his team at the University of Melbourne Dental School , who developed Recaldent®(CPP-ACP technology). Tooth Mousse® (MI Paste®) contains 10 % of the Recaldent® molecule by weight. Calcium phosphopeptide (CPP) is a milk derived protein able to bind calcium and phosphate ions, and stabilise them as amorphous calcium phosphate (ACP). CPP-ACP adheres intra-orally to plaque pellicle, hydroxyapatite as well as soft tissues. It supplies bioavailable calcium and phosphate into saliva and plaque fluid enabling it to drive remineralisation . In vitro studies demonstrate that when placed on the surface of a tooth, CPP-ACP interacts with hydrogen ions and can diffuse into enamel where it produces subsurface mineral gains .
Tooth Mousse Plus® (MI Paste Plus®) contains 900 parts per million fluoride in a molar ratio with the calcium and phosphate of 5 calcium, 3 phosphate and 1 fluoride which is reported by Reynolds and co-workers as the ideal ratio for building fluorapatite [18, 19].
The development of the GC products Tooth Mousse® (MI Paste®) and Tooth Mousse Plus® (MI Paste Plus®) is to be applauded as scientific innovation is critical in the quest to improve the oral health of patients. However when the dental team use and recommend products for patient care there must be sound scientific evidence to support their treatment planning decisions and advice. CPP-ACP in the form of Tooth Mousse® (MI Paste®) and Tooth Mousse Plus® (MI Paste Plus®) are widely recommended for the prevention of early dental caries. The manufacturer instructions recommend Tooth Mousse® (MI Paste®) for patients of any age except those with milk protein allergies but limits the indication of Tooth Mousse Plus® (MI Paste Plus®) to patients over six years of age because of the fluoride content. These products are much more expensive to use than fluoride products, so it is important to examine the evidence supporting their general usage. To this end a systematic review on the specific use of these two products for caries prevention and treatment has been undertaken, in order to determine whether their efficacy warrants use in general dental practice.
The aim of the systematic review is to answer the question. “Is there sufficient clinical evidence available to support the use of Tooth Mousse® (MI Paste®) and Tooth Mousse Plus® (MI Paste Plus®) over a routine oral care regimen for the prevention and treatment of early dental caries?”
A broad search strategy using Medline via OvidSP and EMBASE was performed in order to capture all published studies to related Casein Phosphopeptide-Amorphous Calcium Phosphate (See Additional file 1). In addition to the above searches the terms “CPP ACP” and “casein phosphopeptide amorphous calcium phosphate” were searched using PREMEDLINE and the Cochrane Central Register of Controlled Trials. From these searches – one record from PREMEDLINE was identified as relevant to this review, whilst the Cochrane Database of Systematic Reviews identified a protocol for a systematic review entitled “Non fluoride topical remineralising agents containing calcium and/or phosphate for controlling dental caries . This review by the Cochrane collaboration aims to evaluate non-fluoride topical remineralising agents containing any formulation of calcium and/or phosphate at any concentration and in any topically-applied delivery vehicle and as such has a broader scope than the focus of this review. The inclusion and exclusion criteria used to filter the identified studies can be found in Table 1.
The Cochrane Collaboration’s tool for assessing risk of bias was utilized in the analysis . The papers included in the final review were assessed independently by both authors (SR and AB) for risk of bias.
A broad search of the literature was carried out in December 2013 that identified 7576 articles of which the majority were duplicates. Once these duplicates were removed and the remainder limited to those where CPP-ACP was the primary focus and published in English, 172 articles were identified for closer inspection. The PREMEDLINE search identified one additional paper. Of the 173 articles, the inclusion and exclusion criteria in Table 1 were applied which led to 28 articles being excluded immediately as they were review articles, case reports or letters to the editor.
All of the 145 articles remaining were studied by title and abstract as an initial filter. As the current systematic review is focussed entirely on the CPP-ACP formulations of Tooth Mousse® (MI Paste®) and Tooth Mousse Plus® (MI Paste Plus®) – all studies employing any other formulations of CPP-ACP including solutions, chewing gum and dentifrice were excluded. This filter decreased the number of articles to 29. These 29 articles were studied in full text, nine of which were excluded as they were either in vitro studies or in situ studies utilising bovine enamel, giving 20 studies dating from 2007 to 2013 for final review (Fig. 1). Eight of the twenty studies were excluded – the titles and reasons for exclusion are summarised in Table 2. Andersson et al.  did not use Tooth Mousse® (MI Paste®) or Tooth Mousse Plus® (MI Paste Plus®) but instead utilised a proprietary CPP–ACP dental crème which is either no longer readily available or has been discontinued. Robertson et al.  delivered the MI Paste Plus® in preformed trays, which does not follow the manufacturer’s directions for use. The remaining six [24–29] studies were found on closer examination to have used outcome measures not recognised as clinical care measures or employed artificially demineralised tooth substance in an ‘in situ’ model which were exclusion criteria (See Table 1). Both authors (SR and AB) reviewed the final 20 studies independently and reached consensus on which papers were included in the final review. Of the 12 studies available for this systematic review, three studies reported on prevention [30–32] (Table 3) and nine reported on the treatment or regression of caries [33–41] (Table 4).
Two of the three prevention studies were double-blind randomized controlled trials in populations of pre-school children [31, 32]. These studies found no significant benefits in the use of Tooth Mousse® (MI Paste®) over standard brushing with either 1000 ppm  or 400 ppm  fluoride toothpaste. The authors concluded that there was insufficient evidence to justify the daily use of Tooth Mousse® (MI Paste®) to control dental caries in these populations. The other prevention study published by Uysal et al.  was the in vivo study comparing the use of Tooth Mousse® or a 5 % sodium fluoride gel with a control group to prevent white spot lesions. The results of the in vitro study described in this article were not considered or included in this systematic review. In the in vivo study, patients used a non-fluoride toothpaste and did not receive any oral hygiene instruction. This study showed a statistically significant difference in the enamel microhardness of premolar teeth extracted after the 60 day test period in both the Tooth Mousse® and fluoride gel groups, compared to the control group, but no significant difference between the test groups.
Nine studies [33–41] reported on the treatment or regression of dental caries (Table 4). In the majority of studies fluoride toothpaste was used by participants in all the study groups. However, one study  did not specify whether fluoride toothpaste was used, a second study did not fully specify the use of fluoride toothpaste in all groups  and in another  a non-fluoride toothpaste was used in the test group but fluoride toothpaste was used in the control group.
All except two [34, 39] of the nine studies reported on the regression of white spot lesions in orthodontic patients. This body of evidence, containing seven clinical studies [33, 35–38, 40, 41] of variable strength of evidence utilised either visual scoring or fluorescence techniques for the assessment of dental caries. Some were compared with placebo pastes and others with different preventive products and/or control groups. Of these seven studies, four showed a significant advantage from the use of Tooth Mousse® in the regression of white spot lesions in orthodontic patients over 12 weeks to 6 months [33, 37, 38, 40].
The remaining three studies reported no significant difference between the Tooth Mousse® (MI Paste®) or Tooth Mousse Plus® (MI Paste Plus®) group and control/placebo group over periods of four weeks to three months [35, 36, 41].
Altenburger et al.  reported the remineralization of demineralized enamel fissures in 32 young adults using Tooth Mousse® using both laser fluorescence and visual classification. The Tooth Mousse® group showed significant improvements in laser fluorescence but no difference was noted by the visual scoring at 2 and 3-weeks when compared to the control group.
Krithikadatta et al.  carried out a pilot study on 45 adolescent dental students with occlusal white spot lesions, comparing Tooth Mousse® and Tooth Mousse Plus® to a 0.5 % fluoride mouthrinse. All three groups showed highly significant remineralising potential over the 30 day test period, but Tooth Mousse® and Tooth Mousse Plus® were significantly more effective than the fluoride mouthrinse.
Of the twelve studies included in this systematic review, three studies were direct comparisons of Tooth Mousse® versus a control group [34, 36, 40] and two studies versus a placebo crème [31, 33]. The remaining six studies compared the efficacy of Tooth Mousse® (MI Paste®) and/or Tooth Mousse Plus® (MI Paste Plus®) to other products and techniques with or without a control group - including fluoride toothpaste , fluoride mouthrinse [38, 39], fluoride gel , fluoride varnish , chlorhexidine gel  and microabrasion . The studies by Beerens et al. , Krithidkadatta et al. , and Huang et al.  involved comparisons with Tooth Mousse Plus® (MI Paste Plus®) - containing 900 ppm Fluoride, all other studies utilised only the non-fluoride containing Tooth Mousse® (MI Paste®).
With regard to safety, no serious side effects or adverse events were reported in any of the studies included in the final review. However, five studies [35, 37, 39–41] did not report side effects or adverse events in their papers. One study  recorded one participant with non-serious gastro-intestinal symptoms that were possibly related to the use of Tooth Mousse® and another  made the statement “although CPP-ACP had side effects” but did not make any reference to what the side effects were.
Figure 2 indicates that the prevention studies included in our review were classified as having a low risk of bias, although questions are raised on the Uysal et al.  research on possible selection and performance bias and Plonka et al.  has a question mark over outcome assessment. The regression studies do not show such good results (Fig. 3) with over half having questionable scores for selection bias and the majority having high risk of performance bias.
The strength of evidence of the group of studies included in this systematic review are further weakened by short observation periods (five studies with duration shorter than 3 months [30, 34, 36, 38, 41]), varying outcome measures (clinical indices [31–34, 39, 40], enamel microhardness , laser and light-induced fluorescence [34–36, 39, 40] and visual scoring of photographs [36–38, 41]) and small number of total participants (939 participants for the three prevention studies [30–32] and 542 participants for the nine regression studies [33–41]).
The initial literature search on CPP-ACP yielded a huge number (7576) of publications, however a close scrutiny of the results identified 172 articles that were worthy detailed inspections. Ultimately, 20 articles were selected but eight studies (Table 2) were excluded, giving just 12 papers to consider, three focusing on prevention and nine on controlling dental caries.
If the research data for the prevention of dental caries is assessed, two of the studies [31, 32] which were randomised controlled trials (over 12 and 24 months respectively), reported that Tooth Mousse® did not offer a benefit in terms of a reduction in dental caries for young children over brushing with a fluoride toothpaste. Whilst the third prevention study  reported enamel demineralisation (over a relatively short period of 60 days) in a group of orthodontic patients and once again a fluoride product performed just as well as Tooth Mousse®. Therefore, it would be unwise to recommend Tooth Mousse® (MI Paste®) for the prevention dental caries.
One might also consider it somewhat unusual that the bulk of the evidence on remineralisation studies comes from orthodontic patients who are a very select group of individuals undergoing specialist dental care and not typical of the general population. However it would be unwise to dismiss the results because of the narrow specificity of the target group as it would reduce the data set to two studies. If one considers the orthodontic publications there is a some degree of evidence for the benefits of regression of white spot lesions, with four studies [33, 37, 38, 40] showing positive results and three [35, 36, 41] showing no significant difference to the control groups. When the three studies [35, 39, 41] utilising Tooth Mouth Plus® (MI Paste Plus®) are considered – Krithikadatta et al.  was the only one with a direct comparison between Tooth Mousse® and Tooth Mousse Plus®. The results of this study did not show a significant difference between the non-fluoride and fluoride-containing forms of the CPP-ACP crème and the authors suggested that further studies would be required to confirm these results.
There is a wide variation in the study designs, blinding, protocols and outcome measures in this group of studies making meta-analysis impossible. Clearly, more randomised longer-term trials are required utilizing Tooth Mousse® (MI Paste®) and Tooth Mousse Plus® (MI Paste Plus®) in accordance with the manufacturer’s instructions to clarify the benefits of use in orthodontic patients. In the general population, those individuals at high risk of developing dental caries are commonly of low socio-economic status and have less disposable income for oral care products. Whilst Tooth Mousse® (MI Paste®) has the advantage of being fluoride-free, making it suitable for use in very young children, the risk of development of fluorosis of the permanent teeth from the excessive ingestion of fluoride toothpaste is not a concern for children 6 years of age and older. The two papers [31, 32] in this review that studied the efficacy of Tooth Mousse® (MI Paste®) in children under 6 years of age do not support its use over the twice-daily use of either 1000 ppm  or 400 ppm  fluoride toothpaste. As it is also much more expensive than fluoride toothpaste the recommendation of this product in very young children cannot be supported.
With regard to the benefits of Tooth Mousse® (MI Paste®) or Tooth Mousse Plus® (MI Paste Plus®) in people 6 years of age and above, we certainly require more work to support its general use for the prevention and treatment of early caries apart from perhaps those patients undergoing orthodontic care which is often the province of more affluent individuals.
The risk of bias assessment raises important issues with the regression studies, and clearly more robust and well-executed randomised studies are required.
The findings of this systematic review suggest there is a lack of evidence to support the use of Tooth Mousse® (MI Paste®) over a routine preventive fluoride regimen for the prevention of early dental caries. With regard to the use of Tooth Mousse® (MI Paste®) and Tooth Mousse Plus® (MI Paste Plus®) for the regression of white spot lesions associated with orthodontic treatment there is a tendency towards a benefit for their use but the quality of evidence is limited. Furthermore, at this time there is a lack of support for the use of fluoride-containing formulation - Tooth Mousse Plus® (MI Paste Plus®) over Tooth Mousse® (MI Paste®). New products require testing over time and the lack of sufficient high level clinical evidence for the efficacy of these specific casein phosphopeptide amorphous calcium phosphate-containing products remains a limitation. Further well-designed randomized controlled trials are required prior to the widespread recommendation of Tooth Mousse® (MI Paste®) or Tooth Mousse Plus® (MI Paste Plus®) for the prevention and treatment of early dental caries in the general population.
Casein phosphopeptide-amorphous calcium phosphate
Decayed/missing/filled teeth index
Amorphous calcium phosphate
parts per million
Davies RM, Blinkhorn AS. Preventing dental caries: Part 1 the scientific rationale for preventive advice. Dental Update. 2013;40(9):719. -720, 722, 724-716.
Davies MJ, Spencer AJ, Slade GD. Trends in dental caries experience of school children in Australia--1977 to 1993. Aust Dent J. 1997;42(6):389–94.
Lader D, Chadwick B, Chestnutt I, Harker R, Morris J, Nuttal N, et al. In: Office for National Statistics SSD, editor. Children’s Dental Health in the United Kingdom, 2003. Summary Report [computer file]. London, United Kingdom: Office for National Statistics SSD; 2011.
Marthaler TM. Changes in dental caries 1953-2003. Caries Res. 2004;38(3):173–81.
Griffin SO, Griffin PM, Swann JL, Zlobin N. New coronal caries in older adults: implications for prevention. J Dent Res. 2005;84(8):715–20.
Milsom KM, Blinkhorn AS, Tickle M. The incidence of dental caries in the primary molar teeth of young children receiving National Health Service funded dental care in practices in the North West of England. Br Dent J. 2008;205(7):E14. discussion 384-385.
Walsh T, Worthington HV, Glenny AM, Appelbe P, Marinho VC, Shi X. Fluoride toothpastes of different concentrations for preventing dental caries in children and adolescents. Cochrane Database Syst Rev. 2010;1:CD007868.
Marinho VC, Higgins JP, Logan S, Sheiham A. Fluoride gels for preventing dental caries in children and adolescents. Cochrane Database Syst Rev. 2002;2:CD002280.
Marinho VC, Higgins JP, Logan S, Sheiham A. Fluoride varnishes for preventing dental caries in children and adolescents. Cochrane Database Syst Rev. 2002;3:CD002279.
Marinho VC, Higgins JP, Logan S, Sheiham A. Fluoride mouthrinses for preventing dental caries in children and adolescents. Cochrane Database Syst Rev. 2003;3:CD002284.
Davies RM, Davies GM, Ellwood RP. Prevention. Part 4: Toothbrushing: what advice should be given to patients? Br Dent J. 2003;195(3):135–41.
Walsh LJ. Preventive dentistry for the general dental practitioner. Aust Dent J. 2000;45(2):76–82.
Azarpazhooh A, Main PA. Pit and fissure sealants in the prevention of dental caries in children and adolescents: a systematic review. Journal. 2008;74(2):171–7.
Evans RW, Pakdaman A, Dennison PJ, Howe EL. The caries management system: an evidence-based preventive strategy for dental practitioners. Appl Adults Aust Dent J. 2008;53(1):83–92.
Reynolds EC, Cai F, Cochrane NJ, Shen P, Walker GD, Morgan MV, et al. Fluoride and casein phosphopeptide-amorphous calcium phosphate. J Dent Res. 2008;87(4):344–8.
Cochrane NJ, Reynolds EC. Calcium phosphopeptides -- mechanisms of action and evidence for clinical efficacy. Adv Dent Res. 2012;24(2):41–7.
Kargul B, Altinok B, Welbury R. The effect of casein phosphopeptide-amorphous calcium phosphate on enamel surface rehardening. An in vitro study. Eur J Paediatric Dent. 2012;13(2):123–7.
Reynolds EC. Calcium phosphate-based remineralization systems: scientific evidence? Aust Dent J. 2008;53(3):268–73.
Cross KJ, Huq NL, Stanton DP, Sum M, Reynolds EC. NMR studies of a novel calcium, phosphate and fluoride delivery vehicle-alpha(S1)-casein(59-79) by stabilized amorphous calcium fluoride phosphate nanocomplexes. Biomaterials. 2004;25(20):5061–9.
Parnell C, Gugnani N, Sherriff A, James P, Beirne P. Non-fluoride topical remineralising agents containing calcium and/or phosphate for controlling dental caries (Protocol). Cochrane Database Syst Rev. 2012(3).
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Andersson A, Skold-Larsson K, Hallgren A, Petersson LG, Twetman S. Effect of a dental cream containing amorphous cream phosphate complexes on white spot lesion regression assessed by laser fluorescence. Oral Health Prevent Dent. 2007;5(3):229–33.
Robertson MA, Kau CH, English JD, Lee RP, Powers J, Nguyen JT. MI Paste Plus to prevent demineralization in orthodontic patients: a prospective randomized controlled trial. Am J Orthod Dentofac Orthopedics. 2011;140(5):660–8.
Kitasako Y, Cochrane NJ, Khairul M, Shida K, Adams GG, Burrow MF, et al. The clinical application of surface pH measurements to longitudinally assess white spot enamel lesions. J Dent. 2010;38(7):584–90.
Marchisio O, Esposito MR, Genovesi A. Salivary pH level and bacterial plaque evaluation in orthodontic patients treated with Recaldent products. Int J Dent Hyg. 2010;8(3):232–6.
Thepyou R, Chanmitkul W, Thanatvarakorn O, Hamba H, Chob-Isara W, Trairatvorakul C, et al. Casein phosphopeptide-amorphous calcium phosphate and glass ionomer show distinct effects in the remineralization of proximal artificial caries lesion in situ. Dent Mater J. 2013;32(4):648–53.
Caruana PC, Mulaify SA, Moazzez R, Bartlett D. The effect of casein and calcium containing paste on plaque pH following a subsequent carbohydrate challenge. J Dent. 2009;37(7):522–6.
Ferrazzano GF, Amato I, Cantile T, Sangianantoni G, Ingenito A. In vivo remineralising effect of GC tooth mousse on early dental enamel lesions: SEM analysis. Int Dent J. 2011;61(4):210–6.
Baroni C, Marchionni S, Bazzocchi MG, Cadenaro M, Nucci C, Manton DJ. A SEM and non-contact surface white light profilometry in vivo study of the effect of a creme containing CPP-ACP and fluoride on young etched enamel. Scanning. 2014;36:270–277.
Uysal T, Amasyali M, Koyuturk AE, Ozcan S. Effects of different topical agents on enamel demineralization around orthodontic brackets: an in vivo and in vitro study. Aust Dent J. 2010;55(3):268–74.
Sitthisettapong T, Phantumvanit P, Huebner C, Derouen T. Effect of CPP-ACP paste on dental caries in primary teeth: a randomized trial. J Dent Res. 2012;91(9):847–52.
Plonka KA, Pukallus ML, Holcombe TF, Barnett AG, Walsh LJ, Seow WK. Randomized controlled trial: a randomized controlled clinical trial comparing a remineralizing paste with an antibacterial gel to prevent early childhood caries. Pediatr Dent. 2013;35(1):8–12.
Bailey DL, Adams GG, Tsao CE, Hyslop A, Escobar K, Manton DJ, et al. Regression of post-orthodontic lesions by a remineralizing cream. J Dent Res. 2009;88(12):1148–53.
Altenburger MJ, Gmeiner B, Hellwig E, Wrbas KT, Schirrmeister JF. The evaluation of fluorescence changes after application of casein phosphopeptides (CPP) and amorphous calcium phosphate (ACP) on early carious lesions. Am J Dent. 2010;23(4):188–92.
Beerens MW, van der Veen MH, van Beek H, ten Cate JM. Effects of casein phosphopeptide amorphous calcium fluoride phosphate paste on white spot lesions and dental plaque after orthodontic treatment: a 3-month follow-up. Eur J Oral Sci. 2010;118(6):610–7.
Brochner A, Christensen C, Kristensen B, Tranaeus S, Karlsson L, Sonnesen L, et al. Treatment of post-orthodontic white spot lesions with casein phosphopeptide-stabilised amorphous calcium phosphate. Clin Oral Investig. 2011;15(3):369–73.
Wang JX, Yan Y, Wang XJ. Clinical evaluation of remineralization potential of casein phosphopeptide amorphous calcium phosphate nanocomplexes for enamel decalcification in orthodontics. Chin Med J. 2012;125(22):4018–21.
Akin M, Basciftci FA. Can white spot lesions be treated effectively? Angle Orthod. 2012;82(5):770–5.
Krithikadatta J, Fredrick C, Abarajithan M, Kandaswamy D. Remineralisation of occlusal white spot lesion with a combination of 10 % CPP-ACP and 0.2 % sodium fluoride evaluated using Diagnodent: a pilot study. Oral Health Prevent Dent. 2013;11(2):191–6.
Vashisht R, Indira R, Ramachandran S, Kumar A, Srinivasan MR. Role of casein phosphopeptide amorphous calcium phosphate in remineralization of white spot lesions and inhibition of Streptococcus mutans? J Conservative Dent JCD. 2013;16(4):342–6.
Huang GJ, Roloff-Chiang B, Mills BE, Shalchi S, Spiekerman C, Korpak AM, et al. Effectiveness of MI paste plus and prevident fluoride varnish for treatment of white spot lesions: a randomized controlled trial. Am J Orthod Dentofacial Orthopedics. 2013;143(1):31–41.
Ekstrand KR, Ricketts DN, Kidd EA, Qvist V, Schou S. Detection, diagnosing, monitoring and logical treatment of occlusal caries in relation to lesion activity and severity: an in vivo examination with histological validation. Caries Res. 1998;32(4):247–54.
The publication costs were funded by Colgate Palmolive, Australia.
Sarah Raphael is a consultant for Colgate Palmolive, Australia. However, this work was undertaken as part of her role in the Department of Population Oral Health, University of Sydney. Anthony Blinkhorn is funded by NSW Health, Centre for Oral Health Strategy. The views expressed in this paper are those of the authors’ and do not reflect the policies of either NSW Health or Colgate Palmolive, Australia.
SR was the lead reviewer and prepared the manuscript and AB was the second reviewer and assisted with the preparation of the manuscript. Both authors read and approved the final manuscript.
Availability of data and materials
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Raphael, S., Blinkhorn, A. Is there a place for Tooth Mousse® in the prevention and treatment of early dental caries? A systematic review. BMC Oral Health 15, 113 (2015). https://doi.org/10.1186/s12903-015-0095-6
- Tooth Mousse
- Tooth Mousse Plus
- Dental Caries
- MI Paste
- MI Paste Plus
- Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP)
- Clinical Trials